XML 47 R11.htm IDEA: XBRL DOCUMENT
v3.19.2

Revenues Revenues | 6 Months Ended
--- | ---
Jun. 30, 2019
Revenue from Contract with Customer [Abstract] |
Revenues | Revenues Product Revenues Revenues by product are summarized as follows:
| For the Three Months Ended June 30,
(In millions) | 2019 |  | 2018
| United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 869.8 |  |  | $ | 280.4 |  |  | $ | 1,150.2 |  |  | $ | 825.8 |  |  | $ | 261.0 |  |  | $ | 1,086.8 |
Interferon* | 379.7 |  |  | 174.7 |  |  | 554.4 |  |  | 444.7 |  |  | 180.8 |  |  | 625.5 |
TYSABRI | 264.3 |  |  | 211.0 |  |  | 475.3 |  |  | 265.5 |  |  | 201.7 |  |  | 467.2 |
FAMPYRA | — |  |  | 24.1 |  |  | 24.1 |  |  | — |  |  | 23.0 |  |  | 23.0 |
Subtotal: MS product revenues | 1,513.8 |  |  | 690.2 |  |  | 2,204.0 |  |  | 1,536.0 |  |  | 666.5 |  |  | 2,202.5 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 230.6 |  |  | 257.6 |  |  | 488.2 |  |  | 205.9 |  |  | 216.8 |  |  | 422.7 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |
BENEPALI | — |  |  | 120.3 |  |  | 120.3 |  |  | — |  |  | 115.6 |  |  | 115.6 |
IMRALDI | — |  |  | 47.3 |  |  | 47.3 |  |  | — |  |  | — |  |  | — |
FLIXABI | — |  |  | 16.8 |  |  | 16.8 |  |  | — |  |  | 11.2 |  |  | 11.2 |
Subtotal: Biosimilar product revenues | — |  |  | 184.4 |  |  | 184.4 |  |  | — |  |  | 126.8 |  |  | 126.8 |
Other: |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 3.7 |  |  | 3.7 |  |  | — |  |  | 5.5 |  |  | 5.5 |
Total product revenues | $ | 1,744.4 |  |  | $ | 1,135.9 |  |  | $ | 2,880.3 |  |  | $ | 1,741.9 |  |  | $ | 1,015.6 |  |  | $ | 2,757.5 |
*Interferon includes AVONEX and PLEGRIDY.
| For the Six Months Ended June 30,
(In millions) | 2019 |  | 2018
| United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 1,587.5 |  |  | $ | 561.5 |  |  | $ | 2,149.0 |  |  | $ | 1,554.7 |  |  | $ | 519.0 |  |  | $ | 2,073.7 |
Interferon* | 707.0 |  |  | 348.3 |  |  | 1,055.3 |  |  | 816.0 |  |  | 359.8 |  |  | 1,175.8 |
TYSABRI | 509.3 |  |  | 426.4 |  |  | 935.7 |  |  | 515.2 |  |  | 414.1 |  |  | 929.3 |
FAMPYRA | — |  |  | 47.0 |  |  | 47.0 |  |  | — |  |  | 47.4 |  |  | 47.4 |
ZINBRYTA | — |  |  | — |  |  | — |  |  | — |  |  | 1.4 |  |  | 1.4 |
Subtotal: MS product revenues | 2,803.8 |  |  | 1,383.2 |  |  | 4,187.0 |  |  | 2,885.9 |  |  | 1,341.7 |  |  | 4,227.6 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 453.9 |  |  | 552.8 |  |  | 1,006.7 |  |  | 393.9 |  |  | 392.7 |  |  | 786.6 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |
BENEPALI | — |  |  | 244.3 |  |  | 244.3 |  |  | — |  |  | 236.5 |  |  | 236.5 |
IMRALDI | — |  |  | 83.0 |  |  | 83.0 |  |  | — |  |  | — |  |  | — |
FLIXABI | — |  |  | 31.5 |  |  | 31.5 |  |  | — |  |  | 17.8 |  |  | 17.8 |
Subtotal: Biosimilar product revenues | — |  |  | 358.8 |  |  | 358.8 |  |  | — |  |  | 254.3 |  |  | 254.3 |
Other: |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 7.8 |  |  | 7.8 |  |  | — |  |  | 12.5 |  |  | 12.5 |
Total product revenues | $ | 3,257.7 |  |  | $ | 2,302.6 |  |  | $ | 5,560.3 |  |  | $ | 3,279.8 |  |  | $ | 2,001.2 |  |  | $ | 5,281.0 |
*Interferon includes AVONEX and PLEGRIDY. We recognized revenues from two wholesalers accounting for 30.5% and 18.2% of gross product revenues for the three months ended June 30, 2019, and 30.9% and 16.3% of gross product revenues for the six months ended June 30, 2019. We recognized revenues from two wholesalers accounting for 32.5% and 18.6% of gross product revenues for the three months ended June 30, 2018, and 33.2% and 17.3% of gross product revenues for the six months ended June 30, 2018. An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions) | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Balance, as of December 31, 2018 | $ | 127.8 |  |  | $ | 888.8 |  |  | $ | 34.7 |  |  | $ | 1,051.3 |
Current provisions relating to sales in current year | 308.8 |  |  | 1,391.0 |  |  | 10.6 |  |  | 1,710.4 |
Adjustments relating to prior years | (0.4 | ) |  | (41.9 | ) |  | (0.1 | ) |  | (42.4 | )
Payments/credits relating to sales in current year | (189.6 | ) |  | (827.6 | ) |  | (0.6 | ) |  | (1,017.8 | )
Payments/credits relating to sales in prior years | (121.9 | ) |  | (505.2 | ) |  | (11.9 | ) |  | (639.0 | )
Balance, as of June 30, 2019 | $ | 124.7 |  |  | $ | 905.1 |  |  | $ | 32.7 |  |  | $ | 1,062.5 |
The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions) | As of June 30, 2019 |  | As of December 31, 2018
Reduction of accounts receivable, net | $ | 199.0 |  |  | $ | 176.6 |
Component of accrued expenses and other | 863.5 |  |  | 874.7 |
Total revenue-related reserves | $ | 1,062.5 |  |  | $ | 1,051.3 |
Revenues from Anti-CD20 Therapeutic Programs Revenues from anti-CD20 therapeutic programs are summarized as follows:
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2019 |  | 2018 |  | 2019 |  | 2018
Biogen’s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA | $ | 377.2 |  |  | $ | 359.0 |  |  | $ | 768.0 |  |  | $ | 708.6 |
Other revenues from anti-CD20 therapeutic programs | 199.2 |  |  | 131.4 |  |  | 325.8 |  |  | 225.0 |
Total revenues from anti-CD20 therapeutic programs | $ | 576.4 |  |  | $ | 490.4 |  |  | $ | 1,093.8 |  |  | $ | 933.6 |
For additional information on our collaboration arrangements with Genentech, please read Note 19, Collaborative and Other Relationships, to our consolidated financial statements included in our 2018 Form 10-K. Other Revenues Other revenues are summarized as follows:
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2019 |  | 2018 |  | 2019 |  | 2018
Revenues from collaborative and other relationships: |  |  |  |  |  |  |
(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie | $ | (0.1 | ) |  | $ | (2.5 | ) |  | $ | (0.5 | ) |  | $ | (7.2 | )
Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis | 52.2 |  |  | 14.7 |  |  | 77.0 |  |  | 32.6 |
Other royalty and corporate revenues: |  |  |  |  |  |  |  |  |
Royalty | 2.7 |  |  | 17.3 |  |  | 6.6 |  |  | 27.9 |
Other corporate | 105.2 |  |  | 79.1 |  |  | 369.3 |  |  | 219.7 |
Total other revenues | $ | 160.0 |  |  | $ | 108.6 |  |  | $ | 452.4 |  |  | $ | 273.0 |
Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the three and six months ended June 30, 2019, we recognized $34.5 million and $241.3 million, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business, compared to $47.6 million and $94.6 million, respectively, in the prior year comparative periods. For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, Collaborative and Other Relationships, to these condensed consolidated financial statements. For additional information on our collaboration arrangement with AbbVie Inc., please read Note 19, Collaborative and Other Relationships, to our consolidated financial statements included in our 2018 Form 10-K. For additional information on our manufacturing and supply agreement with Bioverativ, please read Note 3, Hemophilia Spin-Off, to our consolidated financial statements included in our 2018 Form 10-K.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration